Q4 2024 EPS Estimates for Cencora, Inc. Decreased by Leerink Partnrs (NYSE:COR)

Cencora, Inc. (NYSE:COR) – Stock analysts at Leerink Partnrs cut their Q4 2024 earnings per share (EPS) estimates for shares of Cencora in a research report issued to clients and investors on Monday, October 7th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $3.23 per share for the quarter, down from their previous forecast of $3.24. The consensus estimate for Cencora’s current full-year earnings is $13.63 per share. Leerink Partnrs also issued estimates for Cencora’s FY2027 earnings at $18.32 EPS and FY2028 earnings at $20.10 EPS.

Other equities analysts have also issued research reports about the company. Bank of America reissued a “neutral” rating and set a $245.00 price objective (down previously from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Leerink Partners lowered their price target on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research report on Monday. Evercore ISI cut their price objective on shares of Cencora from $270.00 to $250.00 and set an “outperform” rating on the stock in a report on Tuesday. JPMorgan Chase & Co. raised their target price on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. Finally, StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $259.44.

Cencora Trading Up 0.5 %

COR opened at $222.20 on Wednesday. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. Cencora has a 52 week low of $182.75 and a 52 week high of $247.66. The stock has a market cap of $44.32 billion, a PE ratio of 24.31, a PEG ratio of 1.58 and a beta of 0.44. The business has a 50 day moving average of $233.47 and a 200-day moving average of $231.62.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, beating the consensus estimate of $3.18 by $0.16. The firm had revenue of $74.20 billion during the quarter, compared to the consensus estimate of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The company’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.92 earnings per share.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in COR. Rise Advisors LLC purchased a new position in Cencora in the first quarter valued at about $25,000. New Millennium Group LLC purchased a new position in shares of Cencora in the 2nd quarter worth approximately $26,000. TCTC Holdings LLC bought a new position in shares of Cencora during the 1st quarter worth approximately $29,000. TFO Wealth Partners LLC purchased a new stake in Cencora during the first quarter valued at approximately $30,000. Finally, LRI Investments LLC purchased a new stake in Cencora during the first quarter valued at approximately $31,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Activity at Cencora

In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the sale, the insider now directly owns 19,980,000 shares in the company, valued at $4,806,388,800. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, EVP Silvana Battaglia sold 1,473 shares of Cencora stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the sale, the executive vice president now owns 10,948 shares in the company, valued at $2,656,970.12. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the completion of the transaction, the insider now owns 19,980,000 shares in the company, valued at $4,806,388,800. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 4,450,399 shares of company stock valued at $1,070,392,799 over the last 90 days. 15.80% of the stock is owned by corporate insiders.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were given a $0.51 dividend. This represents a $2.04 annualized dividend and a yield of 0.92%. The ex-dividend date of this dividend was Friday, August 9th. Cencora’s dividend payout ratio is presently 22.32%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.